Earlier blood-test detection could help identify pancreatic cancer patients who need more aggressive treatment, an expert ...

Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.

Pancreatic cancer is among the most aggressive types of cancer. Since symptoms appear very late, successful cancer therapy is ...

Treatment for many gastrointestinal cancers is becoming increasingly personalized, thanks to advances in genetic research, targeted therapies and a deeper understanding of how individual tumors behave ...

Imagine diagnosing cancer, tracking its progress, and identifying treatment resistance—all from a simple blood sample. Just a decade ago, this sounded like science fiction. Today, it is becoming an ...

The CodeBreaK 100 study from Amgen Inc. is a Phase 1/2 trial testing sotorasib in advanced solid tumors with a KRAS p.G12C mutation. It aims to find a safe dose, check how the drug behaves in the body ...